Sanofi CEO Chris Viehbacher told employees earlier this year, post-takeover, that Genzyme would remain as a standalone biotechnology unit within Sanofi. He just didn't say how many employees would still be in Genzyme.
Sanofi changes Genzyme reporting - The Boston Globe.
The Boston Globe reports that Genzyme employees were informed that Genzyme would now consist of the personalized genetic health and multiple sclerosis operations -- everyone else in oncology, biosurgery, and renal operations are part of Sanofi.
No word yet on whether any of Genzyme's current 4500 employees in Boston or the other 5500 employees worldwide will be standing alone -- in the unemployment line.
Posted by Bruce Lehr June 1st 2011.
Comments